Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development

Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control

(2016) Ma Carmen Herrero-Sánchez et al.   BRITISH JOURNAL OF HAEMATOLOGY

Profound blockade of T cell activation requires concomitant inhibition of different class I PI3K isoforms

(2015) Belén Blanco et al.   IMMUNOLOGIC RESEARCH

Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function

(2015) Belén Blanco et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia

(2015) Jacky Wong et al.   Oncotarget

Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors

(2014) Joseph D. Valentino et al.   CLINICAL CANCER RESEARCH

Combinatorial action of transcription factors orchestrates cell cycle-dependent expression of the ribosomal protein genes and ribosome biogenesis

(2014) Nagisa Nosrati et al.   FEBS Journal

ZSTK474, a novel PI3K inhibitor, modulates human CD14+ monocyte-derived dendritic cell functions and suppresses experimental autoimmune encephalomyelitis

(2014) Zhenyi Xue et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Effect of Inhibiting the Signal of Mammalian Target of Rapamycin on Memory T Cells

(2014) S. Chen et al.   TRANSPLANTATION PROCEEDINGS

PI3Kδ Inhibition Augments the Efficacy of Rapamycin in Suppressing Proliferation of Epstein−Barr Virus (EBV)+ B Cell Lymphomas

(2013) S. Furukawa et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

(2013) Grace K. Dy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation

(2013) Y. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia

(2013) Susanne Badura et al.   PLoS One

Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment

(2012) Ahmed Abouelnasr et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Transcription Factor Foxo1 Represses T-bet-Mediated Effector Functions and Promotes Memory CD8+ T Cell Differentiation

(2012) Rajesh R. Rao et al.   IMMUNITY

Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function

(2012) Lomon So et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mammalian Target of Rapamycin Integrates Diverse Inputs To Guide the Outcome of Antigen Recognition in T Cells

(2012) A. T. Waickman et al.   JOURNAL OF IMMUNOLOGY

Stimulatory effect of insulin on theca-interstitial cell proliferation and cell cycle regulatory proteins through MTORC1 dependent pathway

(2012) Murugesan Palaniappan et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells

(2011) K. W. Juchem et al.   BLOOD

Novel treatment concepts for graft-versus-host disease

(2011) D. Wolf et al.   BLOOD

Immunotherapy with PI3K Inhibitor and Toll-Like Receptor Agonist Induces IFN- +IL-17+ Polyfunctional T Cells That Mediate Rejection of Murine Tumors

(2011) N. A. Marshall et al.   CANCER RESEARCH

Rapamycin-sensitive signals control TCR/CD28-drivenIfng,Il4andFoxp3transcription and promoter region methylation

(2011) Romana Tomasoni et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation

(2011) Zi Fang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PI3 Kγ controls leukocyte recruitment, tissue injury, and lethality in a model of graft-versus-host disease in mice

(2011) Marina G. M. Castor et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone

(2011) Yuhuan Zheng et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2

(2011) Greg M Delgoffe et al.   NATURE IMMUNOLOGY

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

(2011) Matthew T. Burger et al.   ACS Medicinal Chemistry Letters

Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival

(2010) Bryan C. Barnhart et al.   CANCER BIOLOGY & THERAPY

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

(2010) F. Chiarini et al.   CANCER RESEARCH

Mammalian Target of Rapamycin Protein Complex 2 Regulates Differentiation of Th1 and Th2 Cell Subsets via Distinct Signaling Pathways

(2010) Keunwook Lee et al.   IMMUNITY

The role of mTOR in memory CD8+ T-cell differentiation

(2010) Koichi Araki et al.   IMMUNOLOGICAL REVIEWS

Early events governing memory CD8+ T-cell differentiation

(2010) J. J. Obar et al.   INTERNATIONAL IMMUNOLOGY

mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

(2010) R. J. O. Dowling et al.   SCIENCE

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

(2009) D. W. McMillin et al.   CANCER RESEARCH

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

(2008) Philipp Baumann et al.   EXPERIMENTAL CELL RESEARCH

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS